52 related articles for article (PubMed ID: 19020730)
1. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
Hao HF; Takaoka M; Bao XH; Wang ZG; Tomono Y; Sakurama K; Ohara T; Fukazawa T; Yamatsuji T; Fujiwara T; Naomoto Y
Biochem Biophys Res Commun; 2012 Jul; 423(4):744-9. PubMed ID: 22705303
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.
Minami Y; Kudo M
J Med Ultrason (2001); 2020 Apr; 47(2):257-263. PubMed ID: 32125577
[TBL] [Abstract][Full Text] [Related]
4. Competing Risk Analysis in Lung Cancer Patients Over 80 Years Old Undergoing Surgery.
Hino H; Karasaki T; Yoshida Y; Fukami T; Sano A; Tanaka M; Furuhata Y; Kashiwabara K; Ichinose J; Kawashima M; Nakajima J
World J Surg; 2019 Jul; 43(7):1857-1866. PubMed ID: 30937488
[TBL] [Abstract][Full Text] [Related]
5. [MODIFIED BLUMGART SUTURING TECHNIQUE (NAGOYA METHOD) IN PANCREATICOJEJUNOSTOMY].
Fujii T; Sugimoto H
Nihon Geka Gakkai Zasshi; 2017 Mar; 118(2):203-5. PubMed ID: 30183197
[No Abstract] [Full Text] [Related]
6. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
7. [Kampo medicine (rikkunshito)].
Tominaga K; Tanigawa T; Watanabe T; Fujiwara Y; Arakawa T
Nihon Rinsho; 2015 Jul; 73(7):1179-84. PubMed ID: 26165077
[TBL] [Abstract][Full Text] [Related]
8. Japanese universal health care faces a crisis in cancer treatment.
Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
[No Abstract] [Full Text] [Related]
9. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy.
Niwa Y; Koike M; Iwata N; Kobayashi D; Tanaka C; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Kodera Y
Hepatogastroenterology; 2014 Sep; 61(134):1546-51. PubMed ID: 25436340
[TBL] [Abstract][Full Text] [Related]
10. [Advanced medical care system, highly advanced medical technology assessment system, and investigator-initiated registration-directed clinical trial].
Fujiwara Y
Rinsho Ketsueki; 2011 Oct; 52(10):1721-6. PubMed ID: 21971252
[No Abstract] [Full Text] [Related]
11. Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
Hiraya D; Kagohashi K; Sakamoto N; Kondo T; Satoh H
JOP; 2010 Mar; 11(2):186-8. PubMed ID: 20208333
[No Abstract] [Full Text] [Related]
12. Focal adhesion kinase: from biological functions to therapeutic strategies.
Tan X; Yan Y; Song B; Zhu S; Mei Q; Wu K
Exp Hematol Oncol; 2023 Sep; 12(1):83. PubMed ID: 37749625
[TBL] [Abstract][Full Text] [Related]
13. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
Feng Y; Jiang Y; Hao F
J Transl Med; 2021 Aug; 19(1):373. PubMed ID: 34461940
[TBL] [Abstract][Full Text] [Related]
14. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
15. The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia.
Ghafouri-Fard S; Abak A; Mohaqiq M; Shoorei H; Taheri M
Front Cell Dev Biol; 2021; 9():634512. PubMed ID: 33768092
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
17. The 2016 John J. Abel Award Lecture: Targeting the Mechanical Microenvironment in Cancer.
Majeski HE; Yang J
Mol Pharmacol; 2016 Dec; 90(6):744-754. PubMed ID: 27742780
[TBL] [Abstract][Full Text] [Related]
18. FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDL.
Hu M; Fan M; Zhen J; Lin J; Wang Q; Lv Z; Wang R
J Cell Mol Med; 2017 Mar; 21(3):552-567. PubMed ID: 27704688
[TBL] [Abstract][Full Text] [Related]
19. Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Hu Z; Slayton WB
Front Oncol; 2014; 4():112. PubMed ID: 24860788
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Heffler M; Golubovskaya VM; Dunn KM; Cance W
Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
